References
- Kidney Cancer (Adult) - Renal Cell Carcinoma. American Cancer Society; 2012. http://www.cancer.org/acs/groups/cid/documents/webcontent/003107-pdf.pdf
- Hollenbeak C, Nikkel L, Schaefer E, et al. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma. J Managed Care Pharm 2011;17:610-20
- Gupta K, Miller J, Li J, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:193-205
- Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008;44:2152-61
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, V.2. Fort Washington, PA: National Comprehensive Cancer Network; 2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed September 23, 2010
- Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-a2a compared with sunitinib. Br J Cancer 2010;102:80-6
- Porta C, Szczylik C. Cancer Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 2009;35:297-307
- Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Therapeut 2013;35:1955-63
- Hagiwara M, Hackshaw MD, Oster G. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma. J Med Econ 2013;16:1300-6